Weight Loss
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into the global weight loss drug market. Track pipeline advancements, regulatory approvals, and investment opportunities.
Showing 1–12 of 13 articles
Quick answer
NovaPharmaNews Weight Loss hub for FDA covers 13 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Weight Loss Medications in 2026: GLP-1 Market Shift
GLP-1 usage statistics show broad uptake and mixed clinical signals
Pfizer's Danuglipron Hits Phase 2b Obesity Endpoint
Triple Hormone-Receptor Agonist Retatrutide for Obesity: Phase 3 Results and Market Impact
Pfizer's Berobenatide Obesity Drug: VESPER-3 Data and Competitive Outlook
Pfizer's Berobenatide: Monthly Obesity Drug Shows Promise in Phase 2b
US FDA Proposes New Regulations on Weight-Loss Drug Compounding
Concerns Over GLP-1 Microdoses: A Weight-Loss Doctor's Perspective
FDA Restricts Large-Scale Compounding of Weight Loss Drugs
Eli Lilly’s Triple-G Drug Achieves Bariatric Surgery-Level Weight Loss
Neurocrine Biosciences Begins Phase 1 Trial of NBIP-2118 for Obesity Treatment
Zealand Pharma's Survodutide Achieves 16.6% Weight Loss in Phase 3 Obesity Trial, Outperforming Current GLP-1 Therapies
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.